Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer


Sep 24, 2018--Centrexion Therapeutics Corporation, a company focused on developing novel, non-opioid and non-addictive therapies for the treatment of chronic pain, today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company. "We are very pleased to have Andrew join the Centrexion leadership team," said Jeffrey B. Kindler, chief executive officer of Centrexion Therapeutics.



from Biotech News